HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - A Strong Contender in Affordable Growth Stocks

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) stands out as an attractive option for investors seeking growth at a reasonable price. The biopharmaceutical company, known for its ENHANZE drug delivery technology, combines strong growth metrics with solid fundamentals while trading at what appears to be a reasonable valuation.

Growth Potential

• Revenue has grown by 25.66% over the past year, with an impressive 38.95% average annual growth rate over several years
• Earnings Per Share grew by 46.77% in the past year, with a 30.12% average annual growth rate
• Future EPS growth is projected at 16.77% annually, with revenue expected to grow by 12.63% per year

Attractive Valuation

• P/E ratio of 12.41 compares favorably to both industry peers (96.4% more expensive) and S&P 500 average (27.54)
• Forward P/E of 7.39 suggests the stock is valued very cheaply relative to future earnings
• Enterprise Value to EBITDA ratio indicates HALO is cheaper than 96.76% of industry peers

Strong Fundamentals

• Profitability stands out with Return on Equity of 100.64%, outperforming 99.28% of biotech peers
• Operating margin of 55.10% ranks among the best in the industry
• Healthy balance sheet with current ratio of 8.39 and quick ratio of 7.30
• Debt levels are manageable with a debt to FCF ratio of 3.04

The combination of these factors makes HALOZYME THERAPEUTICS an interesting candidate for investors looking for companies with strong growth potential that aren't overpriced. The company's financial health and profitability provide a solid foundation for continued growth.

Our Affordable Growth screener lists more stocks meeting these criteria and is updated daily. For a complete analysis, see the full fundamental report on HALO.

##Disclaimer This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.